Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Moderna says vaccine 94.5% effective in preventing COVID-19

by REUTERS

Nov 16, 2020 - 3:02 pm GMT+3
In this file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, New York, U.S., July 27, 2020. (AP Photo)
In this file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, New York, U.S., July 27, 2020. (AP Photo)
by REUTERS Nov 16, 2020 3:02 pm
RECOMMENDED
UAE astronaut Sultan AlNeyadi arrives for a news conference at the Museum of the Future in the Gulf emirate of Dubai, on Feb. 2, 2023. (AFP Photo)

Emirati 'Sultan of Space' mulls fasting on ISS during Ramadan

International-Space-Station

Moderna Inc. said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations.

Together with Pfizer Inc. and BioNTech's vaccine, also shown to be more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available by the year's end.

The vaccines, both built using new technology known as messenger RNA or mRNA, represent powerful new tools to fight a pandemic that has infected 54 million people worldwide and killed 1.3 million. The news also comes at a time when COVID-19 cases are soaring, hitting new records in the United States and pushing some European countries back into lockdowns.

"We are going to have a vaccine that can stop COVID-19," Moderna President Stephen Hoge said in a telephone interview.

Moderna's interim analysis was based on 95 infections among trial participants who received either a placebo or the vaccine. Of those, only five infections occurred in those who received the vaccine, which is administered in two shots 28 days apart.

A key advantage of Moderna's vaccine is that it does not need ultra-cold storage like Pfizer's, making it easier to distribute. Moderna expects it to be stable at standard refrigerator temperatures of 2 to 8 degrees Celsius (36 to 48 Fahrenheit) for 30 days and can be stored for up to six months at minus 20 degrees Celsius.

Pfizer’s vaccine must be shipped and stored at minus 70 degrees Celsius, the sort of temperature typical of an Antarctic winter. At standard refrigerator temperatures, it can be stored for up to five days.

The data from Moderna's 30,000 participant-strong trial also showed the vaccine prevented cases of severe COVID-19, a question that still remains with the Pfizer vaccine. Of the 95 cases in Moderna's trial, 11 were severe and all 11 occurred among volunteers who got the placebo.

Moderna, part of the U.S. government's Operation Warp Speed program, expects to produce around 20 million doses of the vaccine for the United States this year, millions of which the company has already made, and is ready to ship if it receives FDA authorization.

"Assuming we get an emergency use authorization, we'll be ready to ship through Warp Speed almost in hours," Hoge said. "So it could start being distributed instantly."

VIDEO — US biotech firm Moderna says its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trialhttps://t.co/PPVKRIUgNA pic.twitter.com/zPM1Ak5Kz2

— DAILY SABAH (@DailySabah) November 16, 2020

DATA DETAILS

The 95 cases of COVID-19 included several key groups who are at increased risk for severe disease, including 15 cases in adults aged 65 and older and 20 in participants from racially diverse groups.

Most side effects were mild to moderate. A significant proportion of volunteers, however, experienced more severe aches and pains after taking the second dose, including about 10% who had fatigue severe enough to interfere with daily activities while another 9% had severe body aches. Most of these complaints were generally short-lived, the company said.

Moderna's data provide further validation of the promising but previously unproven mRNA platform, which turns the human body into a vaccine factory by coaxing cells to make certain virus proteins that the immune system sees as a threat and mounts a response against.

Moderna expects to have enough safety data required for U.S. authorization in the next week or so and the company expects to file for emergency use authorization in the coming weeks.

The United States has the world's highest known number of COVID-19 cases and deaths with more than 11 million infections and nearly 250,000 deaths.

The Trump administration has primarily relied on the development of vaccines and treatments as its response to the pandemic. Moderna has received nearly $1 billion in research and development funding from the U.S. government and has a $1.5 billion deal for 100 million doses. The U.S. government also has an option for another 400 million doses.

The company hopes to have between 500 million and 1 billion doses in 2021, split between its U.S. and international manufacturing sites and dependent in part on demand.

The U.S. government has said COVID-19 vaccines will be provided free to Americans, whether they have health insurance, are uninsured or are covered by government health programs such as Medicare.

Moderna also said it will use its data to seek authorization in Europe and other regions.

Other countries such as China and Russia have already begun vaccinations. Russia licensed its "Sputnik-V” COVID-19 vaccine for domestic use in August before it released data from large-scale trials. It said on Nov. 11 that its vaccine was 92% effective based on 20 infections in its large trial.

RECOMMENDED
UAE astronaut Sultan AlNeyadi arrives for a news conference at the Museum of the Future in the Gulf emirate of Dubai, on Feb. 2, 2023. (AFP Photo)

Emirati 'Sultan of Space' mulls fasting on ISS during Ramadan

International-Space-Station
  • shortlink copied
  • Last Update: Nov 16, 2020 7:22 pm
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 pandemic vaccines&immunity pfizer moderna biontech coronavirus
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    A Turkish police officer stands guard in front of the closed Dutch Consulate in Istanbul, Türkiye, Feb. 1, 2023. (Reuters Photo)

    Türkiye angered over 'intentional' closure of foreign missions

    türkiye-eu-relations
    A Kangal dog and a lamb are seen in Elazığ, eastern Türkiye, Feb. 3, 2023. (IHA Photo)

    Turkish Kangal dog embraces role of mother to lamb

    KANGAL-DOG

    Over 200 flights cancelled in Istanbul due to expected snowstorm

    snowstorm

    'All of Ukraine will burn' due to US supplies: Russia's Medvedev

    Russian-invasion-of-Ukraine
    No Image
    World rallies for Ukraine against Russian invasion
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021